News | March 21, 2022
Hetero gets CDSCO approval to manufacture and sell Sputnik Light in India
Sputnik Light is the first component of Sputnik V
Sputnik Light is the first component of Sputnik V
The facility will produce 150 million vaccine doses per year
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
